The UK Competition Appeal Tribunal confirms a pay-for-delay infringement decision but reduces the fines inflicted (GlaxoSmithKline)

On 10 May 2021, the UK’s Competition Appeal Tribunal (“CAT”) issued its final decision in GSK (Paroxetine) – the long-running saga concerning pay-for-delay patent settlement agreements between GSK and several generics. The CAT upheld the Competition and Markets Authority’s (“CMA”) finding of an infringement of both Articles 101 and 102 TFEU but reduced the level of the fines by 40%. In its infringement decision of 2016, the CMA found GSK and several generic manufacturers to have infringed EU and UK competition law by concluding a series of agreements settling disputes concerning the validity of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Samuel Hall, The UK Competition Appeal Tribunal confirms a pay-for-delay infringement decision but reduces the fines inflicted (GlaxoSmithKline), 10 May 2021, e-Competitions May 2021, Art. N° 101271

Visites 138

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues